SUSAN M. MOLINEAUX, PH.D. - Corporate Board Profile

GERON CORP

Filing Date	Source Excerpt
2013-04-05	Susan M. Molineaux, Ph.D., has served as a director of Geron since September 2012. ... The Board believes Dr. Molineaux's extensive experience in pharmaceutical and oncology drug development ... qualifies Dr. Molineaux to serve as a director. ... In 2012, the members of the Nominating and Corporate Governance Committee were Mr. Fritzky, Ms. Eastham and Dr. Molineaux (who joined in September 2012). ... The following table provides compensation information for the fiscal year ended December 31, 2012 for each non-employee member of the Board. ... Molineaux, Susan $12,526 in fees and $76,244 in option awards totaling $88,770.
2014-04-04	Susan M. Molineaux, Ph.D., has served as a director of Geron since September 2012. She has been Chief Executive Officer and President of Calithera Biosciences, Inc., a privately-held biotechnology company developing oncology therapeutics, since co-founding the company in June 2010. Prior to Calithera, Dr. Molineaux co-founded Proteolix, Inc., a privately-held oncology-oriented biopharmaceutical company, where she served as Chief Scientific Officer from December 2003 until December 2005 and from February 2009 until November 2009, and as President and Chief Executive Officer from January 2006 until February 2009. Dr. Molineaux was responsible for leading the development of Proteolix's second-generation proteasome inhibitor, carfilzomib (now marketed as Kyprolis), for the treatment of multiple myeloma, from discovery through completion of clinical trials for accelerated approval, until the company's acquisition by Onyx Pharmaceuticals, Inc., a global oncology-oriented biopharmaceutical company, in November 2009. From 2000 to 2003, Dr. Molineaux served as Vice President of Biology at Rigel Pharmaceuticals, Inc., a biopharmaceutical company focused on inflammatory and autoimmune diseases. She served as Vice President of Biology at Praelux, Inc. from 1999 to 2000, and from 1994 through 1999, as Vice President of Drug Development at Praecis Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company. From 1989 until 1994, she was a scientist in the Immunology group at Merck & Co., a pharmaceutical company. Dr. Molineaux holds a B.S. in biology from Smith College and a Ph.D. in molecular biology from Johns Hopkins University, and completed a postdoctoral fellowship at Columbia University. She currently serves as the Chairman of Bay Bio, Northern California's Life Science Association, and as a member of the board of directors of We Teach Science, a San Francisco Bay Area mentoring program for students in math and science. The Nominating and Corporate Governance Committee's responsibilities include developing, reviewing and recommending to the Board corporate governance guidelines and principles applicable to Geron, making recommendations to the Board for candidates to be nominated for election or re-election as a director by the stockholders or by the Board and the corporate governance functions described in the Nominating and Corporate Governance Committee's charter. From January 1, 2013 until May 2013, the members of the Nominating and Corporate Governance Committee were Mr. Fritzky, Ms. Eastham and Dr. Molineaux. Mr. Fritzky retired from the Board and the Nominating and Corporate Governance Committee effective as of the date of the Annual Meeting on May 22, 2013, and Dr. Huh joined the Nominating and Corporate Governance Committee on May 22, 2013. The 2013 members of the Nominating and Corporate Governance Committee were, and the 2014 members of the Nominating and Corporate Governance Committee are, "independent" as defined in NASDAQ Rule 5605(a)(2). The following table provides compensation information for the fiscal year ended December 31, 2013, or fiscal 2013, for each non-employee member of the Board who served in such capacity during fiscal 2013. Dr. Scarlett does not receive any compensation for his Board service. The following table sets forth the following information with respect to non-employee directors (nine persons) for the fiscal year ended December 31, 2013: (i) stock options granted under the 2006 Directors' Plan; and (ii) the grant date fair value of stock options granted.
2015-04-03	Susan M. Molineaux, Ph.D., has served as a director since September 2012. She is a member of the Nominating and Corporate Governance Committee. Compensation Table shows total compensation of $101,450.
2016-04-01	Susan M. Molineaux, Ph.D., has served as a director of Geron since September 2012. ... The Nominating and Corporate Governance Committee's responsibilities include developing, reviewing and recommending to the Board corporate governance guidelines and principles applicable to Geron, making recommendations to the Board for candidates to be nominated for election or re-election as a director by the stockholders or by the Board and the corporate governance functions described in the Nominating and Corporate Governance Committee's charter. ... The following table provides compensation information for the fiscal year ended December 31, 2015 ("fiscal 2015"), for each non-employee member of the Board who served in such capacity during fiscal 2015. ... Molineaux, Susan $ 52,500 $ 96,229 $ 148,729
2017-03-24	Susan M. Molineaux, Ph.D. 63 Yes C 2 President, Chief Executive Officer and Director, Calithera Biosciences, Inc. Independent Director ... Geron Committee Memberships - Nominating and Corporate Governance Committee (Chair) ... Director Compensation Table ... Molineaux, Susan $52,500 97,760 $150,260
2018-03-30	Susan M. Molineaux, Ph.D. 64 Yes C 2 President, Chief Executive Officer and Director, Calithera Biosciences, Inc. Independent Director
2019-04-22	Susan M. Molineaux, Ph.D. 65 Yes C 2 President, Chief Executive Officer and Director, Calithera Biosciences, Inc. Independent Director The Board believes Dr. Molineaux’s extensive experience in pharmaceutical and oncology drug development, and her expertise in managing and conducting clinical trials, qualifies Dr. Molineaux to be a director of the Company.
2020-04-14	Dr. Molineaux has served as a director of Geron since September 2012. Dr. Molineaux has been Chief Executive Officer, President and a member of the board of directors of Calithera Biosciences, Inc., a biotechnology company developing oncology therapeutics, since co-founding the company in June 2010. She also serves as a member of the board of directors of Theravance Biopharma, Inc., a biopharmaceutical company located in South San Francisco, since April 2015, where she is a member of the Sciences and Technology Committee, and as a Scientific Advisor to Lightstone Ventures, a private life sciences investment company, since September 2016. Prior to Calithera, Dr. Molineaux co-founded Proteolix, Inc., a privately-held oncology-oriented biopharmaceutical company, where she served as Chief Scientific Officer from December 2003 until December 2005 and from February 2009 until November 2009, and as President and Chief Executive Officer from January 2006 until February 2009, until the company’s acquisition by Onyx Pharmaceuticals, Inc., a global oncology-oriented biopharmaceutical company, in November 2009. Previously, Dr. Molineaux held several senior management positions in the biopharmaceutical industry, including Vice President of Biology at Rigel Pharmaceuticals, Inc., a biopharmaceutical company focused on inflammatory and autoimmune diseases; Vice President of Biology at Praelux, Inc., a biopharmaceutical company; and Vice President of Drug Development at Praecis Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company. Dr. Molineaux holds a B.S. in biology from Smith College, a Ph.D. in molecular biology from Johns Hopkins University, and completed a postdoctoral fellowship at Columbia University. Dr. Molineaux has confirmed to our Board that she is fully committed to continuing to dedicate the required amount of time to fulfill her duties as a director of Geron, including her role as Chair of our Nominating and Corporate Governance Committee. Dr. Molineaux has served on our Board for almost eight years, and during this time, she has thoroughly demonstrated her ability to dedicate sufficient time and focus on her duties as a director of Geron and Chair of our Nominating and Corporate Governance Committee. In each of the years ended December 31, 2019 and 2018, Dr. Molineaux attended 100% of the meetings for Geron’s Board and Geron’s Nominating and Corporate Governance Committee, 100% of the meetings for Calithera’s board, and 100% of the meetings for Theravance’s board and Theravance’s Science and Technology Committee. As President, Chief Executive Officer and director of Calithera, Dr. Molineaux does not serve on any Calithera board committees, and accordingly serves only on board committees for Geron and Theravance. Dr. Molineaux’s duties on Theravance’s Science and Technology Committee are limited in scope and therefore our Board believes that her membership on that committee does not interfere with her ability to reliably devote time to Geron’s Board, as well as Geron’s Nominating and Corporate Governance Committee. In accordance with our Board’s standard practice, Dr. Molineaux reviews scheduled Geron Board and committee meeting dates a year in advance to confirm availability to participate and attend all Board and committee meetings. All the companies for which she serves as a director are located in the San Francisco Bay Area, enabling her to travel and regularly attend Geron’s Board and committee meetings. In addition, each of Geron and Calithera is a smaller reporting company within the meaning of SEC rules and had only 45 and 93 employees, respectively, as of December 31, 2019. Dr. Molineaux does not serve on the board of any privately-held companies. The Board believes Dr. Molineaux’s extensive experience in pharmaceutical and oncology drug development, and her expertise in managing and conducting clinical trials, qualifies Dr. Molineaux to be elected as a director of the Company. The Board and the Nominating and Corporate Governance Committee also believe that Dr. Molineaux provides great value to the Board and contributes significantly to discussions and decision-making. Dr. Molineaux has extensive experience in the biotechnology industry, with current executive experience at Calithera. Accordingly, the Board believes that Dr. Molineaux’s contributions as a director are substantial, based upon her business and scientific expertise acquired in successfully holding executive and leadership positions in biotechnology companies, and her demonstrated reliability and commitment to service on our Board and Nominating and Corporate Governance Committee. Dr. Molineaux’s knowledge of the biotechnology industry and business, and healthcare related issues, combined with her experience as the chief executive officer of a public company, qualify her to be elected as a director of the Company. Dr. Molineaux has confirmed to our Board that she is fully committed to continuing to dedicate the required amount of time to fulfill her duties as a director of Geron, including her role as Chair of our Nominating and Corporate Governance Committee.
2021-03-22	Susan M. Molineaux, Ph.D. 67 Yes C 2 President, Chief Executive Officer and Director, Calithera Biosciences, Inc. Independent Director
2022-03-22	Susan M. Molineaux, Ph.D. 68 Yes C 3 President, Chief Executive Officer and Director, Calithera Biosciences, Inc.; Independent Director Molineaux, Susan 52,500 74,750 127,250
2023-04-12	Susan M. Molineaux, Ph.D. Independent Director 69 Yes AC: C Compensation: $177,700
2024-03-27	Susan M. Molineaux, Ph.D. has served as a director of Geron since September 2012. The Board believes Dr. Molineaux’s extensive experience in pharmaceutical and oncology drug development, her expertise in managing and conducting clinical trials, as well as her knowledge of the biotechnology industry and business, and healthcare related issues, combined with her experience as a female executive officer of a public company provides great value to the Board and contributes significantly to discussions and decision-making, which qualifies her to SERVE as a director. For the year ended December 31, 2023, Dr. Molineaux received $52,496 in cash fees and $293,400 in stock option awards, totaling $345,896.
2025-04-08	Susan M. Molineaux, Ph.D. has served as a director of Geron since September 2012. ... The current members of the Compensation Committee are Dr. Aggarwal, Dr. Spiegel, and Dr. Molineaux. Dr. Molineaux was appointed as a member and Chair of the Compensation Committee effective September 1, 2024. ... The current members of the Nominating and Corporate Governance Committee are Drs. Lawlis, Molineaux, and Spiegel.